Skye Bioscience (SKYE) EBITDA Margin (2013 - 2014)
Skye Bioscience (SKYE) posted quarterly EBITDA Margin of 10.84% for Q2 2014, down 1416.0% year-over-year from 0.82% in Q2 2013, and down 186.14% quarter-over-quarter from 3.79% in Q4 2013.
Skye Bioscience (SKYE) EBITDA Margin (2013 - 2014) Analysis & Trends
Skye Bioscience (SKYE) has reported EBITDA Margin for 2 consecutive years, with 10.84% the latest figure, recorded in Q2 2014.
- In Q2 2014, EBITDA Margin fell 1416.0% year-over-year to 10.84%; the TTM figure through Apr 2014 stood at 32.35% (changed N/A YoY), while the FY2013 annual figure was 1.11%, down 2646.0% from the prior year.
- EBITDA Margin retreated to 10.84% in Q2 2014 per SKYE's latest filing, from 3.79% in the prior quarter.
- Across five years, EBITDA Margin topped out at 3.32% in Q2 2013 and bottomed at 10.84% in Q1 2013.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.88 Bn | 132.03 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 86.62 Bn | 78.62 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 65.28 Bn | 60.10 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 61.39 Bn | 56.25 Bn | 52.00 Mn | -562.07% |
| 5 | BeOne Medicines | 42.11 Bn | 37.01 Bn | 1.53 Bn | 19.06% |
| 6 | Alnylam Pharmaceuticals | 31.37 Bn | 28.06 Bn | 992.69 Mn | 17.93% |
| 7 | BioNTech SE | 28.76 Bn | 10.37 Bn | 668.28 Mn | -35.57% |
| 8 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn | -0.36% |
| 9 | Royalty Pharma | 27.24 Bn | 26.41 Bn | - | 19.75% |
| 10 | Skye Bioscience | 10.74 Mn | 10.74 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2014 | -10.84% |
| Oct 31, 2013 | -3.79% |
| Jul 31, 2013 | 0.82% |
| Apr 30, 2013 | 3.32% |
| Jan 31, 2013 | -10.84% |